
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Alcon AG (ALC)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ALC (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $97.6
1 Year Target Price $97.6
15 | Strong Buy |
6 | Buy |
6 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.18% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 40.31B USD | Price to earnings Ratio 37.67 | 1Y Target Price 97.6 |
Price to earnings Ratio 37.67 | 1Y Target Price 97.6 | ||
Volume (30-day avg) 27 | Beta 0.69 | 52 Weeks Range 78.11 - 100.74 | Updated Date 08/28/2025 |
52 Weeks Range 78.11 - 100.74 | Updated Date 08/28/2025 | ||
Dividends yield (FY) 0.41% | Basic EPS (TTM) 2.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-19 | When - | Estimate 0.7194 | Actual 0.76 |
Profitability
Profit Margin 10.7% | Operating Margin (TTM) 11.17% |
Management Effectiveness
Return on Assets (TTM) 2.64% | Return on Equity (TTM) 4.98% |
Valuation
Trailing PE 37.67 | Forward PE 26.39 | Enterprise Value 44026358176 | Price to Sales(TTM) 4.02 |
Enterprise Value 44026358176 | Price to Sales(TTM) 4.02 | ||
Enterprise Value to Revenue 4.39 | Enterprise Value to EBITDA 16.04 | Shares Outstanding 494400000 | Shares Floating 493297488 |
Shares Outstanding 494400000 | Shares Floating 493297488 | ||
Percent Insiders 0.13 | Percent Institutions 69.48 |
Upturn AI SWOT
Alcon AG

Company Overview
History and Background
Alcon was founded in 1945 as a small pharmacy in Fort Worth, Texas. In 1977, Nestlu00e9 acquired Alcon and significantly expanded its reach. Alcon became an independent company in 2019 after being spun off from Novartis.
Core Business Areas
- Surgical: Focuses on surgical equipment and devices for cataract, refractive, and vitreoretinal surgery.
- Vision Care: Offers contact lenses and lens care products.
Leadership and Structure
David J. Endicott is the current CEO. Alcon operates with a global structure, divided into geographic regions with functional teams supporting each area.
Top Products and Market Share
Key Offerings
- PanOptix IOL: A trifocal intraocular lens used in cataract surgery. Alcon claims to be the leading IOL provider. Competitors include Johnson & Johnson Vision, Bausch + Lomb.
- Dailies Total1: A daily disposable contact lens. Competitors include Johnson & Johnson Acuvue, CooperVision.
- Systane: Over-the-counter artificial tears for dry eye relief. Market share is significant in the OTC eye care market. Competitors include Refresh (Allergan), Blink (Abbott).
Market Dynamics
Industry Overview
The ophthalmic market is driven by an aging population, increasing prevalence of vision disorders, and technological advancements in surgical and vision care solutions.
Positioning
Alcon is a leading player in the ophthalmic market, with a strong portfolio of surgical and vision care products. Its competitive advantages include a global presence, established brand reputation, and continuous innovation.
Total Addressable Market (TAM)
The global ophthalmic market is estimated to be worth around $40 billion. Alcon is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Global brand recognition
- Extensive product portfolio
- Strong research and development capabilities
- Established distribution network
- Leading market positions in key segments
Weaknesses
- Reliance on key products
- Exposure to regulatory risks
- Competition from established and emerging players
- Impact of economic downturns on elective procedures
Opportunities
- Expanding into emerging markets
- Developing innovative products and technologies
- Acquiring complementary businesses
- Capitalizing on the growing demand for eye care solutions
- Strategic partnerships and collaborations
Threats
- Intense competition
- Pricing pressures
- Changes in reimbursement policies
- Product liability claims
- Economic instability
Competitors and Market Share
Key Competitors
- JNJ
- BSY
- COO
Competitive Landscape
Alcon faces intense competition from established players such as Johnson & Johnson and Bausch + Lomb. Alcon's competitive advantages include its broad product portfolio and global presence.
Major Acquisitions
Ivantis, Inc.
- Year: 2022
- Acquisition Price (USD millions): 475
- Strategic Rationale: Expanded Alcon's glaucoma portfolio with Ivantis's Hydrus Microstent.
Growth Trajectory and Initiatives
Historical Growth: Alcon has demonstrated moderate revenue growth in recent years, driven by strong performance in its surgical and vision care segments.
Future Projections: Analyst estimates project continued revenue growth in the mid-single digits, driven by new product launches and expansion into emerging markets.
Recent Initiatives: Recent initiatives include the launch of new contact lens and IOL products, as well as strategic acquisitions to expand its product portfolio and geographic reach.
Summary
Alcon is a strong player in the ophthalmic market with a diverse portfolio and global presence. The company's growth is driven by innovative products and strategic acquisitions. Alcon needs to be wary of competition from Johnson & Johnson and Bausch + Lomb, as well as potential regulatory changes. The lack of dividend payout, although not necessarily critical can make them less desirable against their counterparts.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Alcon Investor Relations
- Market Research Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alcon AG
Exchange NYSE | Headquaters - | ||
IPO Launch date 2019-04-09 | CEO & Director Mr. David J. Endicott | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 25000 | Website https://www.alcon.com |
Full time employees 25000 | Website https://www.alcon.com |
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, grieshaber, MIVS instruments, scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.